The Dual Role of Smad7 in the Control of Cancer Growth and Metastasis

Smad7 was initially identified as an inhibitor of Transforming growth factor (TGF)-β due mainly to its ability to bind TGF-β receptor type I and prevent TGF-β-associated Smad signaling. More recently, it has been demonstrated that Smad7 can interact with other intracellular proteins and regulate also TGF-β-independent signaling pathways thus making a valid contribution to the neoplastic processes in various organs. In particular, data emerging from experimental studies indicate that Smad7 may differently modulate the course of various tumors depending on the context analyzed. These observations, together with the demonstration that Smad7 expression is deregulated in many cancers, suggest that therapeutic interventions around Smad7 can help interfere with the development/progression of human cancers. In this article we review and discuss the available data supporting the role of Smad7 in the modulation of cancer growth and progression.

[1]  K. Hui,et al.  MicroRNA‐216a/217‐induced epithelial‐mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer , 2013, Hepatology.

[2]  Jun Yu,et al.  Inhibitory role of Smad7 in hepatocarcinogenesis in mice and in vitro , 2013, The Journal of pathology.

[3]  Xu Gao,et al.  MicroRNA-25 functions as a potential tumor suppressor in colon cancer by targeting Smad7. , 2013, Cancer letters.

[4]  Samy Lamouille,et al.  TGF-&bgr; signaling and epithelial–mesenchymal transition in cancer progression , 2013, Current opinion in oncology.

[5]  C. Heldin,et al.  APC and Smad7 link TGFβ type I receptors to the microtubule system to promote cell migration , 2012, Molecular biology of the cell.

[6]  I. Giannopoulou,et al.  Differential effect of the expression of TGF‐β pathway inhibitors, Smad‐7 and Ski, on invasive breast carcinomas: relation to biologic behavior , 2012, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[7]  J. Lee,et al.  Smad7 acts as a negative regulator of the epidermal growth factor (EGF) signaling pathway in breast cancer cells. , 2012, Cancer letters.

[8]  H. Ford,et al.  The miR-106b-25 cluster targets Smad7, activates TGF-β signaling, and induces EMT and tumor initiating cell characteristics downstream of Six1 in human breast cancer , 2012, Oncogene.

[9]  M. Neurath,et al.  Smad7 expression in T cells prevents colitis-associated cancer. , 2011, Cancer research.

[10]  M. Macías-Silva,et al.  Inhibitory Smad7: emerging roles in health and disease. , 2011, Current molecular pharmacology.

[11]  Xiaohua Yan,et al.  Smad7: not only a regulator, but also a cross-talk mediator of TGF-β signalling. , 2011, The Biochemical journal.

[12]  Jin-Rong Zhou,et al.  Smad4 inactivation promotes malignancy and drug resistance of colon cancer. , 2011, Cancer research.

[13]  C. Albanese,et al.  Smad7 restricts melanoma invasion by restoring N‐cadherin expression and establishing heterotypic cell–cell interactions in vivo , 2010, Pigment cell & melanoma research.

[14]  S. Park,et al.  Smad7 and Smad6 bind to discrete regions of Pellino-1 via their MH2 domains to mediate TGF-beta1-induced negative regulation of IL-1R/TLR signaling. , 2010, Biochemical and biophysical research communications.

[15]  Yong-jig Cho,et al.  Antimetastatic role of Smad4 signaling in colorectal cancer. , 2010, Gastroenterology.

[16]  R. Wolff,et al.  Increased risk of colon cancer associated with a genetic polymorphism of SMAD7. , 2010, Cancer research.

[17]  M. Lenburg,et al.  Smad signaling is required to maintain epigenetic silencing during breast cancer progression. , 2010, Cancer research.

[18]  J. C. McDermott,et al.  Nuclear Function of Smad7 Promotes Myogenesis , 2009, Molecular and Cellular Biology.

[19]  Gui-ying Zhang,et al.  Smad4/Smad7 balance: a role of tumorigenesis in gastric cancer. , 2009, Experimental and molecular pathology.

[20]  G. Casey,et al.  Association of common genetic variants in SMAD7 and risk of colon cancer. , 2009, Carcinogenesis.

[21]  Z. Meng,et al.  Low-Level Expression of Smad7 Correlates with Lymph Node Metastasis and Poor Prognosis in Patients with Pancreatic Cancer , 2009, Annals of Surgical Oncology.

[22]  Zhenzhen Wang,et al.  Smad7 Is Required for the Development and Function of the Heart* , 2009, Journal of Biological Chemistry.

[23]  N. Deane,et al.  Smad7 induces hepatic metastasis in colorectal cancer , 2008, British Journal of Cancer.

[24]  Zanke,et al.  Genome-wide association scan identifies a colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21 , 2008, Nature Genetics.

[25]  Oliver Sieber,et al.  A genome-wide association study shows that common alleles of SMAD7 influence colorectal cancer risk , 2007, Nature Genetics.

[26]  Seong-Jin Kim,et al.  Smad7 sensitizes tumor necrosis factor induced apoptosis through the inhibition of antiapoptotic gene expression by suppressing activation of the nuclear factor-kappaB pathway. , 2007, Cancer research.

[27]  U. Bogdahn,et al.  Inhibition of Smad7, a negative regulator of TGF-beta signaling, suppresses autoimmune encephalomyelitis , 2007, Journal of Neuroimmunology.

[28]  S. Park,et al.  Smad7 binds to the adaptors TAB2 and TAB3 to block recruitment of the kinase TAK1 to the adaptor TRAF2 , 2007, Nature Immunology.

[29]  Feng Chen,et al.  Smad7 Antagonizes Transforming Growth Factor β Signaling in the Nucleus by Interfering with Functional Smad-DNA Complex Formation , 2007, Molecular and Cellular Biology.

[30]  K. Mohammad,et al.  Stable overexpression of Smad7 in human melanoma cells impairs bone metastasis. , 2007, Cancer research.

[31]  Zhenzhen Wang,et al.  A 4.3 kb Smad7 promoter is able to specify gene expression during mouse development. , 2007, Biochimica et biophysica acta.

[32]  S. Millar.  Smad7: Licensed to Kill β-Catenin , 2006 .

[33]  P. Dijke,et al.  Smad7-Induced β-Catenin Degradation Alters Epidermal Appendage Development , 2006 .

[34]  John C. McDermott,et al.  Smad7 Promotes and Enhances Skeletal Muscle Differentiation , 2006, Molecular and Cellular Biology.

[35]  T. Pawson,et al.  Deletion of Exon I of SMAD7 in Mice Results in Altered B Cell Responses , 2006, The Journal of Immunology.

[36]  Zhenzhen Wang,et al.  In vivo disruption of TGF-beta signaling by Smad7 leads to premalignant ductal lesions in the pancreas. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[37]  K. Miyazono,et al.  Effect of Smad7 expression on metastasis of mouse mammary carcinoma JygMC(A) cells. , 2005, Journal of the National Cancer Institute.

[38]  J. Massagué,et al.  Smad transcription factors. , 2005, Genes & development.

[39]  L. Larue,et al.  Stable overexpression of Smad7 in human melanoma cells inhibits their tumorigenicity in vitro and in vivo , 2005, Oncogene.

[40]  G. Federici,et al.  Post-transcriptional regulation of Smad7 in the gut of patients with inflammatory bowel disease. , 2005, Gastroenterology.

[41]  R. Beauchamp,et al.  Smad7 induces tumorigenicity by blocking TGF-beta-induced growth inhibition and apoptosis. , 2005, Experimental cell research.

[42]  Murray Korc,et al.  Smad7 Abrogates Transforming Growth Factor-β1-mediated Growth Inhibition in COLO-357 Cells through Functional Inactivation of the Retinoblastoma Protein* , 2005, Journal of Biological Chemistry.

[43]  M. Landström,et al.  2-Methoxyestradiol-induced Apoptosis in Prostate Cancer Cells Requires Smad7* , 2005, Journal of Biological Chemistry.

[44]  K. Miyazono,et al.  NEDD4-2 (neural precursor cell expressed, developmentally down-regulated 4-2) negatively regulates TGF-β (transforming growth factor-β) signalling by inducing ubiquitin-mediated degradation of Smad2 and TGF-β type I receptor , 2005 .

[45]  A. Mariani,et al.  Overexpression of the TGF-β antagonist Smad7 in endometrial cancer , 2005 .

[46]  H. Kuwano,et al.  Prognostic value of the expression of Smad6 and Smad7, as inhibitory Smads of the TGF-beta superfamily, in esophageal squamous cell carcinoma. , 2004, Anticancer research.

[47]  H. Friess,et al.  Thioredoxin Is Downstream of Smad7 in a Pathway That Promotes Growth and Suppresses Cisplatin-Induced Apoptosis in Pancreatic Cancer , 2004, Cancer Research.

[48]  K. Choe,et al.  Prognostic significance of the expression of Smad4 and Smad7 in human gastric carcinomas. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[49]  Y. N. Park,et al.  Expression of Smad7 in hepatocellular carcinoma and dysplastic nodules: resistance mechanism to transforming growth factor-beta. , 2004, Hepato-gastroenterology.

[50]  L. Spagnoli,et al.  Induction and regulation of Smad7 in the gastric mucosa of patients with Helicobacter pylori infection. , 2004, Gastroenterology.

[51]  Xu Cao,et al.  GADD34–PP1c recruited by Smad7 dephosphorylates TGFβ type I receptor , 2004, The Journal of cell biology.

[52]  Jennifer Lee,et al.  Smad7 but not Smad6 cooperates with oncogenic ras to cause malignant conversion in a mouse model for squamous cell carcinoma. , 2003, Cancer research.

[53]  R. Herrmann,et al.  SMAD7 is a prognostic marker in patients with colorectal cancer , 2003, International journal of cancer.

[54]  A. Balmain,et al.  Metastasis is driven by sequential elevation of H-ras and Smad2 levels , 2002, Nature Cell Biology.

[55]  T. Macdonald,et al.  Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. , 2001, The Journal of clinical investigation.

[56]  R. Herrmann,et al.  Combined copy status of 18q21 genes in colorectal cancer shows frequent retention of SMAD7 , 2001, Genes, chromosomes & cancer.

[57]  Tomoki Chiba,et al.  Smurf1 Interacts with Transforming Growth Factor-β Type I Receptor through Smad7 and Induces Receptor Degradation* , 2001, The Journal of Biological Chemistry.

[58]  Wei He,et al.  Smads mediate signaling of the TGFβ superfamily in normal keratinocytes but are lost during skin chemical carcinogenesis , 2001, Oncogene.

[59]  K. Williams,et al.  The EGF-CFC family: novel epidermal growth factor-related proteins in development and cancer. , 2000, Endocrine-related cancer.

[60]  J. Wrana,et al.  Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation. , 2000, Molecular cell.

[61]  C. Heldin,et al.  Smad7 mediates apoptosis induced by transforming growth factor β in prostatic carcinoma cells , 2000, Current Biology.

[62]  E. Bottinger,et al.  A mechanism of suppression of TGF–β/SMAD signaling by NF-κB/RelA , 2000, Genes & Development.

[63]  C. Heldin,et al.  Specificity, diversity, and regulation in TGF‐β superfamily signaling , 1999 .

[64]  K. Luo,et al.  Negative Feedback Regulation of TGF-β Signaling by the SnoN Oncoprotein , 1999 .

[65]  H. Friess,et al.  The TGF-β signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer , 1999, Oncogene.

[66]  Qiang Zhou,et al.  The Ski oncoprotein interacts with the Smad proteins to repress TGFbeta signaling. , 1999, Genes & development.

[67]  C. Heldin,et al.  Increased smad expression and activation are associated with apoptosis in normal and malignant prostate after castration. , 1999, Cancer research.

[68]  J. Massagué,et al.  A mechanism of repression of TGFbeta/ Smad signaling by oncogenic Ras. , 1999, Genes & development.

[69]  J. Massagué,et al.  Inhibition of transforming growth factor-β/SMAD signalling by the interferon-γ/STAT pathway , 1999, Nature.

[70]  J. Graff,et al.  Smad3 Mutant Mice Develop Metastatic Colorectal Cancer , 1998, Cell.

[71]  C. Heldin,et al.  Induction of inhibitory Smad6 and Smad7 mRNA by TGF-beta family members. , 1998, Biochemical and biophysical research communications.

[72]  Hiroyuki Miyoshi,et al.  Intestinal Tumorigenesis in Compound Mutant Mice of both Dpc4(Smad4) and Apc Genes , 1998, Cell.

[73]  C. Heldin,et al.  Identification of Smad7, a TGFβ-inducible antagonist of TGF-β signalling , 1997, Nature.

[74]  K. Kinzler,et al.  Frequency of Smad gene mutations in human cancers. , 1997, Cancer research.

[75]  J. Wrana,et al.  The MAD-Related Protein Smad7 Associates with the TGFβ Receptor and Functions as an Antagonist of TGFβ Signaling , 1997, Cell.

[76]  C. Moskaluk,et al.  Homozygous deletion map at 18q21.1 in pancreatic cancer. , 1996, Cancer research.

[77]  L. Liotta,et al.  Tumor invasion and metastasis: an imbalance of positive and negative regulation. , 1991, Cancer research.

[78]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[79]  K. Luo,et al.  Ski and SnoN, potent negative regulators of TGF-β signaling , 2009, Cell Research.

[80]  K. Miyazono,et al.  NEDD4-2 (neural precursor cell expressed, developmentally down-regulated 4-2) negatively regulates TGF-beta (transforming growth factor-beta) signalling by inducing ubiquitin-mediated degradation of Smad2 and TGF-beta type I receptor. , 2005, The Biochemical journal.

[81]  A. Mariani,et al.  Overexpression of the TGF-beta antagonist Smad7 in endometrial cancer. , 2005, Gynecologic oncology.

[82]  C. Heldin,et al.  Transforming growth factor-beta1 (TGF-beta)-induced apoptosis of prostate cancer cells involves Smad7-dependent activation of p38 by TGF-beta-activated kinase 1 and mitogen-activated protein kinase kinase 3. , 2003, Molecular biology of the cell.

[83]  M. Bitzer,et al.  A mechanism of suppression of TGF-beta/SMAD signaling by NF-kappa B/RelA. , 2000, Genes & development.

[84]  J. Massagué.  TGF-beta signal transduction. , 1998, Annual review of biochemistry.

[85]  C. Heldin,et al.  Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling. , 1997, Nature.

[86]  D Falb,et al.  The MAD-related protein Smad7 associates with the TGFbeta receptor and functions as an antagonist of TGFbeta signaling. , 1997, Cell.